SCHEMBL31727227

SCHEMBL31727227

Cc1ccc(S(=O)(=O)N=[S@](C)c2ccc(CO)cc2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 1/20 0.77
▸ KMT2A Q03164 3/20 0.66
▸ MEN1 O00255 2/20 0.66
▸ PIR O00625 1/20 0.60
▸ SMN1; SMN2 Q16637 3/20 0.54
▸ RECQL P46063 1/20 0.54
▸ ALDH1A1 P00352 6/20 0.50
▸ LMNA P02545 2/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ F2 P00734 3/20 0.41
▸ PRSS1 P07477 3/20 0.41
▸ PRSS2 P07478 3/20 0.41
▸ PRSS3 P35030 3/20 0.41
▸ CA1 P00915 2/20 0.41
▸ CA2 P00918 2/20 0.41
▸ CA12 O43570 1/20 0.41
▸ CA4 P22748 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31727390 1.00 CYP2C19 (0.77) CYP2C19KMT2AMEN1PIRSMN1; SMN2
SCHEMBL16317067 0.87 CYP2C19 (1.00) CYP2C19KMT2AMEN1PIRSMN1; SMN2
SCHEMBL17015173 0.87 CYP2C19 (1.00) CYP2C19KMT2AMEN1PIRSMN1; SMN2
SCHEMBL22217122 0.85 CYP2C19 (0.77) CYP2C19KMT2AMEN1PIRSMN1; SMN2
SCHEMBL22217121 0.85 CYP2C19 (0.77) CYP2C19KMT2AMEN1PIRSMN1; SMN2
SCHEMBL1774945 0.80 CYP2C19 (0.84) CYP2C19KMT2AMEN1PIRSMN1; SMN2
SCHEMBL1774946 0.80 CYP2C19 (0.84) CYP2C19KMT2AMEN1PIRSMN1; SMN2
SCHEMBL2940445 0.80 CYP2C19 (0.84) CYP2C19KMT2AMEN1PIRSMN1; SMN2
SCHEMBL17996453 0.80 KMT2A (1.00) CYP2C19KMT2AMEN1PIRSMN1; SMN2
SCHEMBL17015171 0.80 KMT2A (1.00) CYP2C19KMT2AMEN1PIRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001886-A1 ENPP1 INHIBITORS I RE VENTURES I LLC (US) 2026-01-01 — — US disclosed
WO-2025233863-A1 ENPP1 INHIBITORS RE VENTURES I, LLC (US) 2025-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260001886-A1 ENPP1 INHIBITORS I ENPP1, ENPP2, ENPP3 CYP2C19 4384/4885KMT2A 4484/4885MEN1 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback